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Abstract
Patients with diabetes mellitus have diabetic dyslipidemia that occurs due to disturbances in glucose metabolism and
can lead to hypertriglyceridemia (HPTG). Severe HPTG is associated with signiﬁcantly increased risk of developing
acute pancreatitis (AP). Acute pancreatitis (AP) is characterized as an inﬂammatory condition where inactive digestive
enzymes become activated causing pancreatic tissue destruction. Hypertriglyceridemia and the inﬂammatory state that
ensues therein also gives rise to a hypercoagulable state in patients with AP. Splenic vein thrombosis (SVT) is a rare
complication of both AP and chronic pancreatitis (CP). We report a Case of 55-year-old Filipino male with past medical
history of hypertension and uncontrolled type 2 diabetes mellitus (T2D), who presented with abdominal pain and was
found to have diabetic ketoacidosis (DKA), and severe HPTG which led to acute pancreatitis, further complicated by
SVT requiring anticoagulation. Our case highlights the importance of strict glycemic control among diabetic patients, the
prompt management of AP in the setting of HPTG, and treatment of SVT.
Keywords: Multiple myeloma, Vitamin B12, Vitamin B12 deﬁciency, CNS involvement, Leptomeningeal myelomatosis,
Leptomeningeal carcinamatosis

1. Introduction

T

he most common forms of diabetes are type 1
diabetes (T1D) and type 2 diabetes (T2D).1 In
T1D, there is a complete deﬁciency of insulin due to
the pancreatic beta cell destruction, while T2D is
characterized by insulin resistance leading to hyperglycemia. As of 2020, 34 million Americans have
diabetes, and approximately 90e95% of them have
T2D.2 Diabetic ketoacidosis (DKA) is a life-threatening complication of diabetes and although it is
more frequently associated with T1D, it can also
occur, though not as commonly, among patients
with T2D.3 According to CDC surveillance, the
overall, DKA hospitalization rates took a turn toward a steady increase around 2009 to 2914 at an
annual average rate of 6.3%.3 Patient with DM can
have diabetic dyslipidemia due to disturbances
in glucose metabolism, where patients can have
elevated serum triglyceride (TG) levels, low high-

density lipoprotein cholesterol (HDL-C) and high
levels of low-density lipoprotein cholesterol (LDLC).4 Hypertriglyceridemia effects 15e20% of the
adults nationally and is associated with T2D, metabolic syndrome and visceral obesity. Elevated TG
levels further cause damage with release of free fatty
acids (FFA) which cause inﬂammation and
ultimately lead to an increase in insulin resistance
and impairment in the beta cell function of the
pancreas.4 The HPTG associated with diabetes is
classiﬁed into mild to moderate (TG 150e499 pg/
dL), and severe HPTG (TG > 500 pg/dL).4 Prompt
management of HPTG is necessary to prevent the
feared complication of developing acute pancreatitis
(AP) and then its downstream problems. We report
a Case of where the patient with known history of
T2D presented with DKA due to medication
noncompliance, who was found to have severe
HPTG that induced AP ultimately leading to the
development of splenic vein thrombosis.
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2. Case presentation
We report a Case of a 55-year-old Filipino male
with past medical history of hypertension (HTN) and
type 2 diabetes mellitus (DM) who presented with
epigastric pain radiating towards the back, associated
with nausea, and vomiting of two days in duration.
He had history of alcohol abuse but quit over 10 years
ago. Home medications included insulin, metformin,
amlodipine and lisinopril. Patient denied any use of
herbal supplements, or any other new medications.
Physical examination demonstrated a patient in
moderate distress, afebrile with temperature 36.8  C,
an elevated blood pressure (BP) of 151/96 mmHg,
tachycardia with a heart rate (HR) of 103 beats/min,
and tachypnea with a respiratory rate (RR) of 24
breaths/min. His abdomen was non-distended, with
epigastric tenderness without guarding. A right
upper quadrant ultrasound showed normal gallbladder wall thickness, with no gallstones or sludge,
and no pericholecystic ﬂuid. A computed tomography (CT) scan of the abdomen and pelvis with
contrast revealed an acute pancreatitis (Fig. 1),
without evidence of pancreatic necrosis, but with
hepatomegaly and steatosis.
The laboratory parameters were as follows: WBC:
20.7  109/L, Hb: 17.4 g/dL, Hct: 52.0%, PLT: of
556 K/mcL, glucose: 259 mg/dL, urea: 9 mg/dL,
creatinine 0.79 mg/dL, AST: 52 U/L, ALT: 16 U/L,
amylase: 58 U/L, lipase: 2270 U/L, triglyceride (TG):
3355 mg/dL, albumin: 4.1 g/dL, calcium: 8.1 mg/dL,
HbA1c: 15.7%. The blood gas analyses showed the
following: pH: 7.20 mm/Hg, pCO2: 24 mm/Hg, pO2:

79 mm/Hg, HCO3: 9.4 mmol/L and lactate:
1.8 mmol/L. Patient was treated for diabetic ketoacidosis (DKA) with IV Insulin for 2 days, given
ﬂuids, and electrolyte replacement. Patient was also
diagnosed with acute pancreatitis due to hypertriglyceridemia in the setting of DKA and uncontrolled type 2 diabetes mellitus.
His hypertriglyceridemia was managed with
intravenous (IV) regular insulin and heparin drip.
The TG levels began trending down. On Day 2 TG:
1773 mg/dL, Day 3: TG: 628 mg/dL, Day 4: 196 mg/
dL, Day 5: 245 mg/dL and Day 6: 213 mg/dL. Patient
was started on Atorvastatin 40 mg at bedtime daily.
On day 4 patient's white blood cell count increased
to WBC: 18.0  109/L with tachycardia HR 110. A
repeat CT scan of the abdomen and pelvis revealed
worsening pancreatitis with small areas of low attenuation within the pancreatic parenchyma suspicious
for necrosis. A prominent ﬂuid collection was noted
anteriorly between the pancreas and the stomach
which measured approximately 4.6  13.2  7.2 cm.
Another large ﬂuid collection also developed along
the left paracolic gutter measuring 6.2  5.0  19 cm.
In addition, this imaging not only conﬁrmed an early
formation of pseudocyst (Fig. 2), but also demonstrated a new occlusion and thrombosis of the splenic
vein.
The patient was subsequently started on Lovenox
60 mg twice daily for the splenic vein thrombosis
during the remainder of his hospital stay. Patient
was discharged on a six-month course of Xeralto
20 mg daily.

3. Discussion

Fig. 1. Acute Pancreatitis. Pancreas is diffusely edematous with prominent. peripancreatic stranding. stranding and ﬂuid which extends into
the surrounding mesentery and retroperitoneum with some distal
extension along the pericolic gutters. No deﬁnite evidence of pancreatic
necrosis. No focal ﬂuid collection.

Hypertriglyceridemia (HPTG) can be of primary
or secondary types.5 Current classiﬁcation of HPTG
is based on fasting TG levels and can be divided
into moderate (150e1000 mg/dL) and severe
(>1000 mg/dL) forms.6 The primary type of HPTG
is genetic or induced by environmental factors.5
The secondary type of HPTG is a common type of
lipid abnormality seen among patients with metabolic syndrome, visceral obesity, type 2 diabetes
(T2D), cholelithiasis, alcohol, pregnancy, and
medications such as Tamoxifen.5 Upwards of 50%
of patients with T2D have simultaneous HPTG.6
Among the T2D patients it is the insulin resistance
that leads to HPTG with increased peripheral
lipolysis and thereby increased free fatty acid (FFA)
delivery to the liver.5
Acute pancreatitis (AP) is an inﬂammatory condition of the pancreas presenting with abdominal pain
and elevated pancreatic enzymes.7 Gallstones and
alcohol use is associated with approximately two-

Fig. 2. Severe pancreatitis with (new) occlusion of the splenic vein and
new suspected areas of pancreatic necrosis. Prominent increase in peripancreatic ﬂuid and ﬂuid extending along the left paracolic gutter
suspicious for early pseudocyst formation. A: Severe pancreatitis (red
arrow) with interval increase in peripancreatic ﬂuid collection (yellow
arrow), with suspected area of pancreatic necrosis (blue arrow). The
ﬂuid collection is seen anteriorly between the pancreas and the stomach
which measures approximately 4.6  13.2  7.2 cm. B: Splenic vein
thrombosis.

thirds of cases of pancreatitis. Hypertriglyceridemia
(HPTG) is a rare but known cause of AP.8 HPTG has
become the third most common cause of acute
pancreatitis (AP). The risk of developing AP increases
progressively with increasing serum levels of
TG  500 mg/dL. Moderate HPTG is associated with
slightly increased risk of developing AP.6 The risk of
developing AP is between 5 and 20% in patients with
severe HPTG.9 The pathophysiology of HPTGinduced AP (HPTG-AP) is still unclear, but it is
generally accepted that in the setting of excess serum
triglycerides (TG), the pancreatic lipase hydrolyzes
the TG leading to a large accumulation of FFA and
glycerin within the pancreas.5 These FFA are mostly
unsaturated fatty acids (UFA) which trigger an
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inﬂammatory reaction, the release of intracellular
calcium, ultimately causing pancreatic acinar necrosis. With elevated serum FFA levels, FFA molecules
aggregate into micelles which leads to pancreatic
ischemia. The ischemia further triggers acidosis
which activates trypsinogen to become active trypsin
causing pancreatic auto-digestion, hence AP. In
addition, these FFA also directly damage the
pancreatic vascular endothelial cells leading to
vascular leakage and activation of coagulation
cascade.5 There are various complications of AP that
include pseudocyst formation, chronic pancreatitis
(CP), pancreatic necrosis, and complications associated with hypercoagulability such as splenic vein
thrombosis (SVT).10 Hypercoagulability in AP can
present as mild intravenous thrombosis or disseminated intravascular coagulation (DIC). Diabetes
Mellitus (DM) have underlying microvascular complications which may also be associated with
increased risk of developing thrombosis.1 SVT is a
rare complication that can be seen in both AP and
CP.11 Splanchnic vein thrombosis consists of 4 types:
mesenteric vein, splenic vein, portal vein, and hepatic
vein thrombosis.12
SVT is deﬁned as “primary” or “secondary,”
depending on the presence or absence of risk factors.
Pancreatitis is the most common cause of splenic vein
thrombosis.11e13 Other causes of SVT include
pancreatic cancer, lymphoma, and iatrogenic
including post-surgery such as splenectomy, gastrectomy, and splenorenal shunt.10,11,14 Splenic vein
thrombosis in pancreatitis results from inﬂammation
caused due to the anatomic location of the splenic
vein along posterior aspect of the pancreas. The etiology is multifactorial e damage by venous
compression from enlarged lymph nodes, ﬁbrosis,
pseudocysts, or edema.10 Pancreatitis-induced SVT is
reported to have an overall incidence of 14.1%, while
its frequency due to HPTG has been recorded as
3.6%.15,16 Patients may be asymptomatic or symptomatic. Symptomatic patients have upper gastrointestinal bleeding due to esophageal or gastric varices
or hypertensive gastropathy. Patients develop a
localized form of portal hypertension with SVT where
collateral blood ﬂow is formed through splenoportal
or gastroepiploic venous system ultimately leading to
gastric, esophageal, or colonic varices.16 These varices
may serve as a potential source for gastrointestinal
(GI) bleeding, a further complication of SVT. On
physical examination, patients may have evidence of
ascites and splenomegaly.
Clinicians advise anticoagulation in some patients
with acute splenic vein thrombosis, but evidencebased guidelines are lacking. The goal of anticoagulation in this setting is to prevent recurrent
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thrombosis, prevent thrombus extension, and promote recanalization. However, while patients are
often at risk for recurrent thrombosis, they are also
at risk for variceal bleeding. As a result, the decision
to start anticoagulation must be made on a Case-bycase basis.
Ninth edition of the American College of Chest
Physicians Practice Guidelines recommended
treatment with anticoagulants for patients with
symptomatic splanchnic vein thrombosis (Grade
1B) but advised against anticoagulation with
asymptomatic thrombosis (Grade 2C).17,18 However, in a study by Tufano. et al. 35, 521 patients with
symptomatic splanchnic vein thrombosis had a
ratio between VTE recurrence and major bleeding
of 5e10, while in 309 patients with incidental
splanchnic vein thrombosis, this ratio was 15e16.19
The authors of this study proposed that patients
with incidental thrombosis should be treated with
anticoagulants after a careful analysis of risk factors
for hemorrhagic complications.12,19 Splenectomy is
the ﬁrst line treatment in variceal bleeding with
splenic artery embolization and percutaneous
recanalization available as options for non-surgical
candidates.13

4. Conclusion
It is important patients with underlying diabetes
maintain strict glycemic control to prevent downstream cascade of complications such as diabetic
ketoacidosis and hypertriglyceridemia (HPTG).
Moderate to severe HPTG can lead to increased risk
of developing acute pancreatitis (AP). Both acute
and chronic pancreatitis can rarely develop splenic
vein thrombosis in the setting of HPTG. Patients
with splenic vein thrombosis, if symptomatic,
should be treated with anticoagulation. This Case
highlights the importance of considering HPTG is
the etiology of AP and splenic vein thrombosis as a
complication in patients who are diabetic or obese
with metabolic syndrome.
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